Patents by Inventor Andreas Hotter

Andreas Hotter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200140706
    Abstract: A process for producing a three-dimensional object by selectively layer-by-layer solidification of a powdery material layer at the locations corresponding to the cross-section of the object in a respective layer by exposure to electromagnetic radiation. The powdery material comprises at least one polymer which is obtainable from its melt only in substantially amorphous or completely amorphous form, or a polyblend which is obtainable from its melt only in substantially amorphous or completely amorphous form. The powdery material has a specific melting enthalpy of at least 1 J/g.
    Type: Application
    Filed: April 25, 2018
    Publication date: May 7, 2020
    Applicant: EOS GmbH Electro Optical Systems
    Inventors: Andreas Pfister, Andreas Hotter, Peter Keller, Karl Freihart
  • Patent number: 10323056
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: June 18, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Patent number: 10265326
    Abstract: The present invention relates to crystalline form C of avibactam sodium and to a process for its preparation. The invention also concerns a pharmaceutical composition comprising form C and one or more antibacterial agents, wherein at least one antibacterial agent is a beta-lactam antibiotic. The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 23, 2019
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Verena Adamer, Hannes Lengauer
  • Patent number: 10189860
    Abstract: The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 29, 2019
    Inventors: Andreas Hotter, Andrea Thaler, Andrija Lebar, Biljana Jankovic, Klemen Naversnik, Uros Klancar, Zrinka Abramovic
  • Publication number: 20180193351
    Abstract: The present invention relates to crystalline form C of avibactam sodium and to a process for its preparation. The invention also concerns a pharmaceutical composition comprising form C and one or more antibacterial agents, wherein at least one antibacterial agent is a beta-lactam antibiotic. The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Application
    Filed: August 9, 2016
    Publication date: July 12, 2018
    Applicant: Sandoz AG
    Inventors: Andreas Hotter, Verena Adamer, Hannes Lengauer
  • Patent number: 9867829
    Abstract: The present invention relates to a stable pharmaceutical composition comprising amorphous or crystalline linagliptin or a pharmaceutically acceptable salt of linagliptin, mannitol, copovidone, and magnesium stearate, processes for preparing the stable pharmaceutical composition, and a container comprising the stable pharmaceutical composition.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: January 16, 2018
    Assignee: SANDOZ AG
    Inventors: Franz X. Schwarz, Georg Anker, Johann Bacher, Andreas Hotter
  • Publication number: 20170369475
    Abstract: The present invention relates to a hydrate of flibanserin, a process for its preparation and to a pharmaceutical composition comprising the hydrate. The invention further relates to the use of said pharmaceutical composition as a medicament in particular for the treatment of hypoactive sexual desire disorder (HSDD).
    Type: Application
    Filed: June 23, 2016
    Publication date: December 28, 2017
    Applicant: Sandoz AG
    Inventors: Andreas Hotter, Hannes Lengauer, Gerhard Widschwenter
  • Patent number: 9732053
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: August 15, 2017
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas Hotter, Robert Ziegert-Knepper, Verena Adamer, Arthur Pichler
  • Publication number: 20170217987
    Abstract: The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Applicant: Lek Pharmaceuticals d.d.
    Inventors: Andreas Hotter, Andrea Thaler, Andrija Lebar, Biljana Jankovic, Klemen Naversnik, Uros Klancar, Zrinka Abramovic
  • Patent number: 9670188
    Abstract: The present invention relates to an improved large scale process for the preparation of posaconazole form IV.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: June 6, 2017
    Inventor: Andreas Hotter
  • Patent number: 9586369
    Abstract: A method for coating the surfaces of three-dimensional objects with a coating agent is provided, which method is characterized by a blasting of the three-dimensional object, wherein a grainy blasting material that has been mixed with the coating agent is used as blasting medium.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: March 7, 2017
    Assignee: EOS GMBH ELECTRO OPTICAL SYSTEMS
    Inventors: Mandy Gersch, Ilhan Tuncer, Andreas Hotter, Florian Pfefferkorn
  • Patent number: 9534004
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 3, 2017
    Assignee: SANDOZ AG
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Patent number: 9499504
    Abstract: The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2?±0.2° 2? (CuK? radiation)) at 5.5°, 14.8°, 16.7° and 20.0° and processes for obtaining the same.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 22, 2016
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Michael Enders, Ulrich Griesser
  • Publication number: 20160289202
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 6, 2016
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas HOTTER, Robert ZIEGERT, Verena ADAMER, Arthur PICHLER
  • Publication number: 20160200750
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 14, 2016
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Publication number: 20160168133
    Abstract: The present invention relates to an improved large scale process for the preparation of posaconazole form IV.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 16, 2016
    Applicant: Sandoz AG
    Inventor: Andreas Hotter
  • Publication number: 20160145286
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 26, 2016
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Publication number: 20150266841
    Abstract: The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2[2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2?±0.2° 2? (CuK? radiation)) at 5.5°, 14.8°, 16.7° and 20.0° and processes for obtaining the same.
    Type: Application
    Filed: September 18, 2013
    Publication date: September 24, 2015
    Applicant: SANDOZ AG
    Inventors: Andreas Hotter, Michael Enders, Ulrich Griesser
  • Publication number: 20150224102
    Abstract: The present invention relates to a stable pharmaceutical composition comprising amorphous or crystalline linagliptin or a pharmaceutically acceptable salt of linagliptin, mannitol, copovidone, and magnesium stearate, processes for preparing the stable pharmaceutical composition, and a container comprising the stable pharmaceutical composition.
    Type: Application
    Filed: August 12, 2013
    Publication date: August 13, 2015
    Inventors: Franz X. Schwarz, Georg Anker, Johann Bacher, Andreas Hotter
  • Patent number: 9062031
    Abstract: The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 23, 2015
    Assignee: SANDOZ AG
    Inventors: Arthur Pichler, Andreas Hotter, Christoph Langes